Drugs / Danhong injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01681316 | Dec 2012 → Oct 2016 | intermediate coronary syndrome | China Academy of Chinese Medical Sciences | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Danhong injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01681316 ↗ |
| Known as | DHI | “treated by 14-day Danhong injection(DHI), a kind of polypharmacological drug with high quality control, or placebo (0.9% saline)” PMID 34471087 ↗ Sep 2021 |
| Modality | Traditional medicine (herbal / TCM) | “A kind of injection made from two kind of Chinese herbs: salvia miltiorrhiza and safflower” NCT01681316 ↗ |
| Route | Intravenous | “given by continuous IV infusion at 2.5ml/min within 2 hours.” NCT01681316 ↗ |